Skip to main content

Table 2 Patient Demographics

From: Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder

Variable   Black Descent White Descent P-values
   (N = 372) (N = 602)  
Gender Male 264 (71.0%) 399 (66.3%) 0.132
  Female 108 (29%) 203 (33.7%)  
Age (yrs) Mean 39.96 39.79 0.514
  SD 9.48 10.91  
  Median 40.49 39.85  
Weight (kg) Mean 86.62 84.01 0.257
  SD 21.93 20.73  
  Median 82.43 81.12  
BMI (kg/m2)   N = 362 N = 596 0.587
  Mean 29.06 28.47  
  SD 6.95 6.51  
  Median 28.15 27.33  
Geographic Region USA 324 (87%) 416 (69.1%) <0.001
  Europe 4 (1.1%) 107 (17.8%  
  South America 37 (10%) 76 (12.6%)  
  Other 7 (1.9%) 3 (0.5%)  
PANSS Total Mean 88.15 89.27 0.528
  SD 15.45 17.66  
  Median 87.0 88  
PANSS Positive Mean 21.31 21.08  
  SD 5.05 5.98  
  Median 21.5 21  
Diagnosis Schizophrenia 322 (86.6%) 459 (76.3%) <0.001
  Schizoaffective 50 (13.4%) 139 (23.1%) <0.001
  Schizophreniform 0 (0%) 4 (0.7%) 0.298
CGI Score Mean N = 329 N = 505 0.002
  SD 4.42 4.60  
  Median 0.69 0.78  
   4.00 4.00  
# Previous Episodes   N = 184 N = 341 0.296
  Mean 8.53 7.07  
  SD 7.53 8.98  
  Median 6.0 4.0  
Illness Duration   N = 368 N = 600 0.547
  Mean 16.83 15.92  
  SD 10.38 10.43  
  Median 15.45 15.17  
  1. Abbreviations: N = All randomized patients with at least one post-baseline visit; SD = Standard Deviation; BMI = Body max index; PANSS = Positive and negative syndromes scale; CGI = Clinical global impression